- JP-listed companies
- Cash flow
(4893) Cash flow
Market cap
¥6.4B
P/E ratio
Develops cancer immunotherapy treatments for solid tumors using proprietary PRIME technology that enhances immune cell activation and generates revenue through both in-house drug development and technology licensing.
| 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Cash from operations | -777 | -107 | -873 | -888 | -752 |
| Cash from investing | -4 | - | -5 | 1 | -0 |
| Repurchases of common stock | - | - | - | - | -0 |
| Cash from financing | 2,374 | 488 | 1,913 | 3 | -0 |